Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

Fig. 6

Progression-free survival curves (a) and overall survival curves (b) according to the combination of CA19-9 and P-CRP Group A, both CA19-9Low and P-CRPLow; Group B, either CA19-9High or P-CRPHigh; Group C, both CA19-9High and P-CRPHigh; CA19-9, carbohydrate antigen 19–9; irAEs, immune-related adverse events; MST, median survival time; P-CRP, platelet count × serum C-reactive protein level multiplier value; ROC, receiver operating characteristic

Back to article page